Medicamen Biotech Limited

BSE: 531146 NSE: MEDICAMEQ
Medicamen Biotech Limited - pharma in New Delhi, Delhi, India. FY 2026 financials & compliance.
CIN L74899DL1993PLC056594 Incorporated 22 December 1993 ROC Delhi HQ New Delhi, Delhi, India
Active Listed - NSE: MEDICAMEQ · BSE: 531146 Public Limited Company pharma MSME · Medium
Data last updated
Market Cap
₹370 Cr
MEDICAMEQ · NSE
Share Price
₹262.60
-0.21% today
Revenue
₹198 Cr
FY 2025-26 · +21.7% YoY
EBITDA
₹19.59 Cr
Margin 9.9%
Net Profit
₹9.63 Cr
FY 2025-26 · +35.6% YoY
P/E (TTM)
34.0x
P/B 1.3x
Authorised capital
₹15 Cr
Registered with MCA
Paid-up capital
₹13.56 Cr
Issued & subscribed

About Medicamen Biotech Limited

Data last updated:

Medicamen Biotech Limited is a public limited company based in New Delhi, Delhi, India, a subsidiary of Shivalik Rasayan Limited. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 22 December 1993 and has been in existence for over 33 years.

The company is registered with the Registrar of Companies (ROC), Delhi, under CIN L74899DL1993PLC056594. Its GSTIN is 07AAACM1217A1ZB (Delhi). The company holds 5 GST registrations, of which 4 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 531146 and NSE: MEDICAMEQ.

The company has an authorised share capital of ₹15 Cr and a paid-up capital of ₹13.56 Cr. It is led by directors including Ashwani Kumar Sharma (Whole-Time Director) and Vimal Kumar Shrawat.

Its last annual general meeting (AGM) was held on 26 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 1506 Chiranjiv Tower 43 Nehru Place, New Delhi, Delhi, India – 110019.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹197.77 Cr, a growth of 21.7% compared to the previous year. For the same year it recorded a net profit of ₹9.63 Cr (net margin 4.9%) and EBITDA of ₹19.59 Cr (EBITDA margin 9.9%). The net worth stands at ₹275.54 Cr (up 29.3% YoY). Total assets are valued at ₹327.11 Cr (up 31.4% YoY).

The company has about 314 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.

The company is associated with 1 brand: Medicamen. As per MCA filings, the company has open charges of ₹66.43 Cr and satisfied charges of ₹52.09 Cr on record. Court records list 60 cases involving the company, including 33 filed by the company and 27 filed against it; 6 cases are pending. The company has 28 deals on record (26 market trades, 2 acquisitions); the latest was in March 2024. Its 8 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 3 smaller; the largest is Bakson Drugs and Pharmaceuticals Private Limited with revenue of ₹172.81 Cr.

Medicamen Biotech Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-DL-08-0002941). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website medicamen.com.

Company details

CIN L74899DL1993PLC056594
Registration Number 056594
Incorporation Date 22 December 1993
ROC Delhi
Listing Status Listed - Listed on NSE (MEDICAMEQ); Listed on BSE (531146)
Company Status Active
Date of Last AGM 26 September 2025
Date of Balance Sheet 31 March 2026
Parent Company Shivalik Rasayan Limited
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-DL-08-0002941
Key People
Ashwani Kumar Sharma Whole-Time Director Vimal Kumar Shrawat Director Sumita Dwivedi Director

Recognitions & Rankings of Medicamen Biotech

MSME (Udyam registered) Ministry of MSME
Category
Medium (2024-25)
Udyam number
UDYAM-DL-08-0002941

Contact details

Medicamen Biotech Limited's registered office is in New Delhi, Delhi. Its website is medicamen.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    medicamen.com
  • Social Media
  • Registered Address
    1506 Chiranjiv Tower 43 Nehru Place, New Delhi, Delhi, India – 110019
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Medicamen Biotech Limited, buy the company report.

Comprehensive company report
Medicamen Biotech Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Medicamen Biotech operates one associated brand: Medicamen. Each brand links to its own profile.

BrandDescriptionWebsite
Medicamen
Manufacturer of tablets, capsules, syrups, ointments and ORSmedicamen.com

Business activity

The main business activity of Medicamen Biotech is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Medicamen Biotech Limited, buy the company report.

Financials of Medicamen Biotech Limited

FY 2025-26 filings available

Medicamen Biotech Limited reported revenue of ₹197.77 Cr (up 21.7% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹198 Cr
+21.7% YoY
EBITDA
₹19.59 Cr
+35.9% YoY
Profit After Tax
₹9.63 Cr
+35.6% YoY
Net Worth
₹276 Cr
+29.3% YoY
Total Assets
₹327 Cr
+31.4% YoY
Total Debt
₹49.20 Cr
+45.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue198163179141115113126
Revenue growth+21.7%-9.4%+27.3%+22.0%+2.4%-10.2%-
EBITDA19.5914.4223.5124.3524.1019.6919.46
EBITDA margin+9.9%+8.9%+13.1%+17.3%+20.9%+17.5%+15.5%
Profit before tax11.989.8713.0817.0518.1116.4117.97
Net profit9.637.1010.9414.8614.9112.1413.32
Net profit margin+4.9%+4.4%+6.1%+10.6%+12.9%+10.8%+10.6%
EPS (₹)7.225.598.6011.7312.199.9310.88
Balance sheet
Total assets327249240221174153134
Net worth276213207193146133121
Total debt49.2033.7731.1125.7125.8018.8211.47
Cash & bank31.263.7614.7920.783.823.893.09
Net working capital17911610510671.0655.1756.76
Cash flow
Cash from operations(33.17)(8.16)(6.74)(6.29)4.1112.7712.80
Cash from investing(3.04)(1.40)(5.56)(5.88)(8.47)(17.81)(37.29)
Cash from financing63.72(1.47)6.3129.134.305.8419.06
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue47.9060.6546.9147.1743.0429.6145.1444.74
Revenue growth (YoY)+11.3%+104.8%+3.9%+5.4%-0.0%---
Other income0.861.740.530.370.475.230.140.29
EBITDA4.335.444.385.164.61(1.61)6.705.31
EBITDA margin+9.0%+9.0%+9.3%+10.9%+10.7%-5.4%+14.8%+11.9%
Depreciation1.791.731.831.861.800.482.212.61
Interest0.830.380.970.991.150.650.761.04
Profit before tax2.575.072.112.682.132.493.871.95
Tax0.730.610.470.570.530.630.961.05
Net profit1.844.461.642.111.601.862.910.90
EPS (₹)1.363.281.211.561.181.472.300.71
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue179151172138115110117
Revenue growth+18.1%-12.1%+25.0%+19.4%+4.8%-6.1%-
EBITDA18.2917.1027.2424.6124.1220.0318.12
EBITDA margin+10.2%+11.3%+15.8%+17.9%+20.9%+18.2%+15.4%
Profit before tax11.5512.7716.8817.3318.1316.7516.60
Net profit9.419.4413.2915.0114.9312.4812.29
Net profit margin+5.3%+6.2%+7.7%+10.9%+12.9%+11.3%+10.5%
EPS (₹)6.947.4310.4611.8612.2010.2210.03
Balance sheet
Total assets320247241221175154135
Net worth280218209194148134122
Total debt37.8527.4129.8125.7125.8018.8211.47
Cash & bank31.083.5814.6220.443.813.082.23
Net working capital16510898.9410270.5754.5655.95
Cash flow
Cash from operations(29.26)(2.63)(0.25)(3.50)4.8112.9811.71
Cash from investing(2.85)(1.72)(8.71)(7.54)(8.47)(17.81)(39.35)
Cash from financing59.61(6.68)3.1427.674.395.6821.36
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue43.8554.6843.4942.2338.4526.0041.1442.84
Revenue growth (YoY)+14.0%+110.3%+5.7%-1.4%-7.3%---
Other income0.861.730.530.370.475.220.140.29
Total expenses39.0750.5538.4137.1834.4127.0934.9036.30
EBITDA4.784.135.085.054.04(1.09)6.246.54
EBITDA margin+10.9%+7.6%+11.7%+12.0%+10.5%-4.2%+15.2%+15.3%
Depreciation1.741.731.751.811.770.472.172.57
Interest0.640.600.780.840.560.620.731.01
Profit before tax3.263.533.082.772.183.043.483.25
Tax0.730.550.480.560.530.630.960.98

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 05 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue47.9060.6546.9147.1743.0429.6145.1444.74
Revenue growth (YoY)+11.3%+104.8%+3.9%+5.4%-0.0%---
Other income0.861.740.530.370.475.230.140.29
EBITDA4.335.444.385.164.61(1.61)6.705.31
EBITDA margin+9.0%+9.0%+9.3%+10.9%+10.7%-5.4%+14.8%+11.9%
Depreciation1.791.731.831.861.800.482.212.61
Interest0.830.380.970.991.150.650.761.04
Profit before tax2.575.072.112.682.132.493.871.95
Tax0.730.610.470.570.530.630.961.05
Net profit1.844.461.642.111.601.862.910.90
EPS (₹)1.363.281.211.561.181.472.300.71
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue198163179141115113126
Revenue growth+21.7%-9.4%+27.3%+22.0%+2.4%-10.2%-
Other income3.116.242.332.461.720.751.94
Total expenses17814815611791.3593.03106
Employee cost0.0030.8729.0720.1514.509.009.52
EBITDA19.5914.4223.5124.3524.1019.6919.46
EBITDA margin+9.9%+8.9%+13.1%+17.3%+20.9%+17.5%+15.5%
Depreciation7.227.077.096.375.772.522.50
Interest3.503.725.673.391.941.510.93
Profit before tax11.989.8713.0817.0518.1116.4117.97
Tax2.193.323.582.323.204.274.69
Net profit9.637.1010.9414.8614.9112.1413.32
Net profit margin+4.9%+4.4%+6.1%+10.6%+12.9%+10.8%+10.6%
EPS (₹)7.225.598.6011.7312.199.9310.88
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital13.5612.7112.7112.6512.2212.2212.22
Reserves & surplus253200194178134121109
Shareholders' funds (net worth)276213207193146133121
Minority interest0.000.000.000.000.000.000.00
Secured loans46.4033.7731.1125.7125.8018.829.97
Unsecured loans2.800.000.000.000.000.001.50
Total debt49.2033.7731.1125.7125.8018.8211.47
Total liabilities327249240221174153134
Assets
Gross block14413913713012411657.74
Net block84.6687.1191.8592.6692.4889.6433.69
Capital work in progress0.000.000.000.000.000.0040.50
Investments0.000.000.000.000.000.000.00
Inventories70.0862.1459.3845.0627.015.2016.96
Sundry debtors81.8368.9055.2665.2663.2252.5549.96
Cash & bank balances31.263.7614.7920.783.823.893.09
Loans & advances40.5629.7630.1832.2728.9834.3934.12
Total current assets22416516016312396.03104
Total current liabilities44.8748.1254.7057.7351.9740.8647.37
Net working capital17911610510671.0655.1756.76
Total assets327249240221174153134
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash3.7614.7920.783.823.893.098.52
Net cash from operating activities(33.17)(8.16)(6.74)(6.29)4.1112.7712.80
Net cash from investing activities(3.04)(1.40)(5.56)(5.88)(8.47)(17.81)(37.29)
Net cash from financing activities63.72(1.47)6.3129.134.305.8419.06
Net change in cash27.50(11.03)(5.99)16.95(0.07)0.80(5.43)
Closing cash31.263.7614.7920.783.823.893.09
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+21.7%-9.4%+27.3%+22.0%+2.4%-10.2%-
EBITDA growth+35.9%-38.7%-3.5%+1.0%+22.4%+1.2%-
PBT growth+21.4%-24.5%-23.3%-5.9%+10.4%-8.7%+2.5%
Net income growth+35.6%-35.1%-26.4%-0.3%+22.8%-8.9%-
Revenue CAGR (3Y)+12.0%+12.1%+16.7%+3.9%-2.0%--
EBITDA CAGR (3Y)-7.0%-15.7%+6.1%+7.8%+11.3%--
Profitability & leverage
Net income margin+5.0%+4.0%+5.3%+10.5%+12.9%+10.8%+10.6%
Return on capital employed-+5.6%+8.1%+10.4%+12.3%+12.5%+16.2%
Return on net worth-+3.1%+4.7%+8.7%+10.7%+9.6%+12.8%
Debt / equity-0.150.140.150.160.120.11
Long-term debt / equity-0.010.010.020.040.030.01
Interest cover28.2950.6134.5318.8510.588.795.48
Efficiency & per share
Fixed asset turnover-1.181.341.110.961.302.41
Inventory turnover-2.683.433.917.1710.177.79
Debtors turnover-2.622.982.191.992.202.69
EPS (₹)7.225.598.6011.7312.199.9310.88
Dividend per share (₹)1.001.001.001.001.001.000.50
Book value per share (₹)0.00167.57162.79150.82119.89108.7899.22
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue43.8554.6843.4942.2338.4526.0041.1442.84
Revenue growth (YoY)+14.0%+110.3%+5.7%-1.4%-7.3%---
Other income0.861.730.530.370.475.220.140.29
Total expenses39.0750.5538.4137.1834.4127.0934.9036.30
EBITDA4.784.135.085.054.04(1.09)6.246.54
EBITDA margin+10.9%+7.6%+11.7%+12.0%+10.5%-4.2%+15.2%+15.3%
Depreciation1.741.731.751.811.770.472.172.57
Interest0.640.600.780.840.560.620.731.01
Profit before tax3.263.533.082.772.183.043.483.25
Tax0.730.550.480.560.530.630.960.98
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue179151172138115110117
Revenue growth+18.1%-12.1%+25.0%+19.4%+4.8%-6.1%-
Other income3.106.232.302.461.720.751.91
Total expenses16113414511391.3390.1299.22
Employee cost0.0021.5722.1218.5714.508.799.29
EBITDA18.2917.1027.2424.6124.1220.0318.12
EBITDA margin+10.2%+11.3%+15.8%+17.9%+20.9%+18.2%+15.4%
Depreciation7.066.967.016.355.772.522.50
Interest2.783.605.653.391.941.510.93
Profit before tax11.5512.7716.8817.3318.1316.7516.60
Tax2.143.333.592.333.204.274.35
Net profit9.419.4413.2915.0114.9312.4812.29
Net profit margin+5.3%+6.2%+7.7%+10.9%+12.9%+11.3%+10.5%
EPS (₹)6.947.4310.4611.8612.2010.2210.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital13.5612.7112.7112.6512.2212.2212.22
Reserves & surplus258205196180136122110
Shareholders' funds (net worth)280218209194148134122
Secured loans37.8527.4129.8125.7125.8018.829.97
Unsecured loans0.000.000.000.000.000.001.50
Total debt37.8527.4129.8125.7125.8018.8211.47
Total liabilities320247241221175154135
Assets
Gross block14213813613012411657.74
Net block83.8486.3191.1192.3692.4889.6433.69
Capital work in progress0.000.000.000.000.000.0040.50
Investments8.068.067.764.082.062.062.06
Inventories70.0862.1459.3345.0627.015.2016.96
Sundry debtors64.9158.6248.2960.2361.1849.7543.93
Cash & bank balances31.083.5814.6220.443.813.082.23
Loans & advances40.0529.1830.1432.2428.9834.3934.12
Total current assets20615415215812192.4297.24
Total current liabilities41.5745.9453.4455.6250.4137.8641.29
Net working capital16510898.9410270.5754.5655.95
Total assets320247241221175154135
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash3.5814.6220.443.813.082.238.52
Net cash from operating activities(29.26)(2.63)(0.25)(3.50)4.8112.9811.71
Net cash from investing activities(2.85)(1.72)(8.71)(7.54)(8.47)(17.81)(39.35)
Net cash from financing activities59.61(6.68)3.1427.674.395.6821.36
Net change in cash27.50(11.04)(5.82)16.630.730.85(6.29)
Closing cash31.083.5814.6220.443.813.082.23
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+18.1%-12.1%+25.0%+19.4%+4.8%-6.1%-
EBITDA growth+7.0%-37.2%+10.7%+2.0%+20.4%+10.5%-
PBT growth-9.6%-24.4%-2.6%-4.4%+8.2%+0.9%-5.3%
Net income growth-0.3%-29.0%-11.5%+0.5%+19.6%+1.6%-
Revenue CAGR (3Y)+9.1%+9.5%+16.1%+5.5%-2.0%-0.4%+12.5%
EBITDA CAGR (3Y)-9.4%-10.8%+10.8%+10.7%+11.4%+6.1%+16.1%
Profitability & leverage
Net income margin+5.3%+6.2%+7.7%+10.9%+12.9%+11.3%+10.4%
Return on capital employed-+6.7%+9.8%+10.5%+12.2%+12.6%+15.0%
Return on net worth-+4.4%+6.6%+8.8%+10.6%+9.7%+11.7%
Debt / equity-0.130.140.150.160.120.11
Long-term debt / equity-0.000.000.020.040.030.01
Interest cover24.7635.5027.9318.5710.578.625.95
Efficiency & per share
Fixed asset turnover-1.111.301.080.961.272.25
Inventory turnover-2.493.303.837.179.947.28
Debtors turnover-2.833.182.272.082.352.69
EPS (₹)6.947.4310.4611.8612.2010.2210.03
Dividend per share (₹)1.001.001.001.001.001.000.50
Book value per share (₹)0.00171.17164.54152.30121.18109.98100.25

To see the full year-wise statements and ratios of Medicamen Biotech Limited, buy the company report.

Board of directors of Medicamen Biotech Limited

Medicamen Biotech has 10 current directors and 30 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Vimal Kumar Shrawat
Also directs: Shivalik Rasayan Limited, Chem Pharma Healthcare Private Limited
Director11 Feb 20197 Years 8 MonthsCurrent
Sumita Dwivedi
Also directs: Shivalik Rasayan Limited, Skyforge System Solutions LLP
Director13 Nov 20187 Years 11 MonthsCurrent
Sangeeta Bishnoi
Also directs: Shivalik Rasayan Limited
Director11 Feb 20197 Years 8 MonthsCurrent
Ravi Kumar Bansal
Also directs: Shivalik Rasayan Limited
Director30 May 20197 Years 5 MonthsCurrent
Sanjay Bansal
Also directs: J B Spintex Private Limited, Genius Constructions Private Limited, Versatile Land Base Private Limited and 1 more
Director27 Feb 201610 Years 8 MonthsCurrent
Ashwani Kumar Sharma
Also directs: Shivalik Rasayan Limited, Medicamen Life Sciences Private Limited, Growel Remedies Limited
Whole-Time Director31 Dec 201510 Years 10 MonthsCurrent
Showing 6 of 10 current directors. View all directors

Peer comparison

Medicamen Biotech Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Medicamen Biotech Limitedthis company₹197.77 Cr (FY 2026)₹9.63 Cr4.9%21.7%314New Delhi, Delhi, India
Bakson Drugs and Pharmaceuticals Private Limited₹172.81 Cr (FY 2025)15.0%New Delhi, Delhi, India
Shree Krishnakeshav Laboratories Limited₹170.52 Cr (FY 2025)13.0%Ahmedabad, Gujarat, India
Natural Capsules Limited₹169.91 Cr (FY 2025)8.0%Bengaluru, Karnataka, India
Stericon Pharma Private Limited₹169.15 Cr (FY 2025)21.0%Bangalore, Karnataka, India
Eurolife Healthcare Private Limited₹168.9 Cr (FY 2020)-20.0%Thane, Maharashtra, India
Group Pharmaceuticals Limited₹168.31 Cr (FY 2025)10.0%Thane, Maharashtra, India
DWD Pharmaceuticals Limited₹166.47 Cr (FY 2025)10.0%Mumbai, Maharashtra, India
Inject Care Parenterals Private Limited₹165.13 Cr (FY 2025)13.0%Vapi, Gujarat, India

To see the full peer comparison of Medicamen Biotech Limited, buy the company report.

Auditor

Medicamen Biotech Limited is audited by Rai Qimat & Associates for the financial year 2024.

Auditor firmFinancial yearFirm registration number
Rai Qimat & AssociatesFY 2024013152C

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 40.50%, foreign institutional investors hold 0.10%, domestic institutional investors hold 0.40% and retail and other public shareholders hold 59.00%.

Promoters: 40.50%DII (Domestic Institutional): 0.40%FII (Foreign Institutional): 0.10%Retail & Others: 59.00%
Sep 2026
QUARTER
40.50% Promoters
0.40% DII (Domestic Institutional)
0.10% FII (Foreign Institutional)
59.00% Retail & Others
Promoter holding - history
Now 40.50% · Sep 2026High 40.50% · Dec 2025Low 40.50% · Dec 2025
39%39.8%40.5%41.3%42%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 40.50%Mar 2026: 40.50%Jun 2026: 40.50%Sep 2026: 40.50%40.50%40.50%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters40.50%40.50%40.50%40.50%
Public59.50%59.50%59.50%59.50%

Charges & borrowings

Open charges
₹66.43 Cr
Satisfied charges
₹52.09 Cr
Breakdown by lending institutions
Others₹46.08 Cr
Citi Bank N.A.₹20.00 Cr
Hdfc Bank Limited₹0.35 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
06 May 2026101322836Others₹52.83 LakhOpen
28 Mar 2025101091431Others₹9 CrOpen
21 Mar 2025101078022Others₹1.17 CrOpen
10 May 2023100755628Hdfc Bank Limited₹35 LakhOpen
19 Mar 2021100449354Citi Bank N.A.₹20 CrOpen

To see the full charge records of Medicamen Biotech Limited, buy the company report.

Total charge records: 11 View all charges

Deals & funding

Medicamen Biotech Limited has 28 deals on record (26 market trades, 2 acquisitions); the latest was in March 2024.

Total deals
28
Market trades
26
Acquisitions
2

Deals on record (5 of 28)

WhenDealAmountParties
Mar 2024Market trade₹8.44 CrBuyer: Shivalik Rasayan Limited
Seller: Growel Remedies Limited
Nov 2016Market trade₹2.76 CrBuyer: JMP Securities Private Limited
Seller: JMP Securities Private Limited
Jan 2016Market trade₹1.11 CrBuyer: NBN Fintrade Private Limited , an individual
Seller: NBN Fintrade Private Limited
Nov 2015Market trade₹34.6 LakhBuyer: Rajasthan Global Securities Private Limited
Seller: Geometric Securities and Advisory Private Limited
Sep 2015Market trade₹35.2 LakhBuyer: Rajasthan Global Securities Private Limited

To see the full deal history of Medicamen Biotech Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Medicamen Biotech Limited was last rated by Crisil on 20 Dec 2019.

Rating agencyRated onRating
Crisil20 Dec 2019

To see the full credit ratings and regulatory alerts of Medicamen Biotech Limited, buy the company report.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Medicamen Biotech Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

Group structure & subsidiaries

Medicamen Biotech has 1 subsidiary company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

1
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Medicamen Life Sciences Private LimitedU24290DL2022PTC403121

To see the full group structure of Medicamen Biotech Limited, buy the company report.

Employees & EPFO

Medicamen Biotech Limited has a workforce of 314 employees on its EPFO records as of Feb 27, 2025, across 3 active EPFO establishments.

Employee count
314
Active EPFO establishments
3
Employee growth
-22.47%

GST

Medicamen Biotech has 5 GST registrations: 4 active and 1 cancelled or inactive.

Total GSTINs
5
Active
4
Cancelled / inactive
1
GSTINStateStatusRegistered on
07AAACM1217A1ZBDelhiActive01 Jul 2017
05AAACM1217A1ZFUttarakhandActive01 Jul 2017
08AAACM1217A1Z9RajasthanActive01 Jul 2017
05AAACM1217A2ZEUttarakhandActive19 Apr 2018

To see the full GST registrations and return filing status of Medicamen Biotech Limited, buy the company report.

Recent activity

Medicamen Biotech Limited has 57 board changes on record since 1994: 35 appointments and 22 cessations. The latest: Shaival Saurabh was appointed as Director on 12 Aug 2025.

Charges
A charge with Others amounted to Rs. 0.53 Cr with Charge ID 101322836 was registered on 06 May 2026.
Filing
Medicamen Biotech Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Delhi I.
AGM
Medicamen Biotech Limited last Annual general meeting of members was held on 26 Sep 2025 as per latest MCA records.
Appointed
Shaival Saurabh was appointed as Director.
Appointed
Sham Goel was appointed as Director.
Charges
A charge with Others of Rs. 9.00 Cr registered on 28 Mar 2025 with Charge ID 101091431 was modified on 30 Jul 2025.
Charges
A charge with Citi Bank N.A. of Rs. 20.00 Cr registered on 19 Mar 2021 with Charge ID 100449354 was modified on 23 Jun 2025.
Charges
A charge registered on 25 Nov 2019 via Charge ID 100303030 with Others was fully satisfied on 15 May 2025.
Charges
A charge with Others amounted to Rs. 9.00 Cr with Charge ID 101091431 was registered on 28 Mar 2025.
Charges
A charge with Others amounted to Rs. 1.17 Cr with Charge ID 101078022 was registered on 21 Mar 2025.
Charges
A charge registered on 02 Jul 2015 via Charge ID 10587692 with Indian Bank was fully satisfied on 23 Jun 2023.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.35 Cr with Charge ID 100755628 was registered on 10 May 2023.

67 earlier events are in the company report.

News

Frequently asked questions

Medicamen Biotech is an active public limited company based in New Delhi, Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 22 December 1993 (33+ years old) and is registered under CIN L74899DL1993PLC056594. Listed on BSE: 531146 and NSE: MEDICAMEQ.

Medicamen Biotech reported revenue of ₹197.77 Cr for FY 2025-26 (up 21.7% YoY) based on consolidated financials.

Medicamen Biotech has 10 current directors:

The latest financial statements of Medicamen Biotech on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 26 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Medicamen Biotech is 07AAACM1217A1ZB, registered in Delhi. The company has 5 GST registrations in all, of which 4 are active and 1 is cancelled or inactive. Other active GSTINs include 05AAACM1217A1ZF (Uttarakhand), 08AAACM1217A1Z9 (Rajasthan), 05AAACM1217A2ZE (Uttarakhand).

The CIN (Corporate Identification Number) of Medicamen Biotech is L74899DL1993PLC056594. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Medicamen Biotech is a listed company as per MCA records. Its shares are listed on both BSE (code: 531146) and NSE (symbol: MEDICAMEQ).

Medicamen Biotech has 60 court cases on record: 33 filed by the company and 27 filed against it. 6 are pending. Most are in the high courts.

Medicamen Biotech was incorporated on 22 December 1993, making it 33+ years old. It is registered with the Registrar of Companies, Delhi.

Medicamen Biotech has 28 deals on record (26 market trades, 2 acquisitions); the latest was in March 2024.

The peers of Medicamen Biotech by revenue are Bakson Drugs and Pharmaceuticals Private Limited, Shree Krishnakeshav Laboratories Limited, Natural Capsules Limited, Stericon Pharma Private Limited, Eurolife Healthcare Private Limited and 3 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).